



Gritstone to Participate in Precision Oncology Panel at BIO CEO & Investor Conference

February 8, 2022

EMERYVILLE, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive Officer, will participate in a panel discussion on the role and future of precision oncology at the 2022 BIO CEO & Investor Conference, taking place at the Marriott Marquis in New York City from February 14 to 15 and virtually through February 17, 2022.

The panel, titled "Treating Cancer Through Precision Oncology", will take place from 11 a.m. to 11:45 a.m. EST Monday, February 14, 2022, and will be accessible live to conference registrants. An archived replay will be added to <https://ir.gritstonebio.com/investors/events> approximately 30 days after the event.

For additional information on the BIO CEO & Investor Conference, visit <http://www.bio.org/events/bio-ceo-investor-conference>.

About Gritstone

Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Gritstone develops its products by leveraging two key pillars—first, a proprietary machine learning-based platform, Gritstone EDGE™, which is designed to predict antigens that are presented on the surface of cells, such as tumor or virally-infected cells, that can be seen by the immune system; and, second, the ability to develop and manufacture potent immunotherapies utilizing these antigens to potentially drive the patient's immune system to specifically attack and destroy disease-causing cells. The company's lead oncology programs include an individualized neoantigen-based immunotherapy, GRANITE, and an "off-the-shelf" shared neoantigen-based immunotherapy, SLATE, which are being evaluated in clinical studies. Within its infectious disease pipeline, Gritstone is advancing CORAL, a COVID-19 program to develop a second-generation vaccine, with support from departments within the National Institutes of Health (NIH), the Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI) and through a license agreement with La Jolla Institute for Immunology. Additionally, the company has a global collaboration for the development of a therapeutic HIV vaccine with Gilead Sciences. For more information, please visit www.gritstonebio.com.

Gritstone Contacts

Media:

Dan Budwick

1AB

(973) 271-6085

dan@1abmedia.com

Investors:

George E. MacDougall

Director, Investor Relations & Corp Comms

Gritstone bio, Inc.

IR@gritstone.com

